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Rho GTPases are proteins that in response to diver-
se stimuli control key signaling and structural 
aspects of the cell. Although early studies had pro-
posed a role for Rho GTPases in cellular transfor-
mation, this effect was underestimated by the fact
that no genetic mutations affecting Rho-encoding
genes was found in human tumors. However, in re-
cent years a high incidence of overexpression of dif-
ferent members of the family of Rho GTPases in
human tumors has been detected which is leading
to a great interest in the cellular effects elicited by
these oncoproteins. As well, the characterization
of downstream effectors and upstream regulators of
Rho GTPases provides crucial clues on the specific
cellular effects that permit aberrant cellular growth
and tumorigenesis. A direct link between the func-
tions of some of these signaling elements and regu-
lation of the cell cycle, cytoskeletal rearrangements
and cell adhesion has been observed in distinct ty-
pes of human tumors. Provided this information, a
number of drugs that affect Rho signaling at diffe-
rent levels have been described with promising in
vivo antitumoral activity. In this review, the current
evidence of dysregulation of Rho signaling in hu-
man tumors is assembled.
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GTPasas Rho en carcinogénesis humana:
una cuestión de exceso
Las GTPasas Rho regulan un alto número de proce-
sos de señalización y estructurales de la célula en
respuesta a diversos estímulos. El hecho de que no
se haya detectado mutación alguna en la secuencia
primaria de ningún miembro de la familia de GT-
Pasas Rho ha conllevado a que se subestimase su
posible papel en la biología de diversos tumores hu-
manos. Sin embargo, el creciente número de traba-
jos recientes que describen una elevada incidencia
muy alta de sobreexpresión de las proteínas Rho en
un alto número de tumores ha suscitado mucho in-
terés en la comunidad científica. La caracterización
de proteínas efectoras y de la señalización depen-
diente de Rho ha permitido identificar los mecanis-
mos a través de los cuales esta familia de proteínas
inducen una proliferación aberrante y, en última
instancia, el desarrollo y progresión del tumor. La
relación entre la actividad de alguna de las proteí-
nas efectoras de Rho con el ciclo celular, reorganiza-
ción del citoesqueleto y la adhesión celular ha sido
observada en diversos tipos de tumores humanos.
Además se ha sintetizado una serie de compuestos
que afectan las rutas de señalización dependientes
de Rho a varios niveles y que muestran una activi-
dad antitumoral in vivo prometedora. En esta revi-
sión realizamos un detallado resumen del conoci-
miento actual acerca de la desregulación de las
proteínas Rho en tumores humanos. 
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and membrane trafficking1-8. Indeed, these proteins
are essential for processes such as embryonic deve-
lopment, immune and inflammatory responses, tissue
differentiation, wound healing, and tissue morphoge-
nesis. This ability to act as general modulators of es-
sential biological processes confers them with the ca-
pacity to play important roles in tumor biology and
other human pathologies (for an excellent review on
Rho signaling in disease see reference9). 
Several members of the Rho family of GTPases have
been cloned to date. These include RhoA, RhoB,
INTRODUCTION 
Rho GTPases mediate housekeeping aspects of cell
biology including cell size, mitosis/meiosis, prolifera-
tion, apoptosis/survival, cell polarity, cell adhesion,
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drolysis of GTP to yield GDP, and binding to one form
or another of the nucleotide is the basis of their regu-
lated function. From a functional sense, Rho GTPases
cycle between an active GTP-bound state, and an
inactive GDP-bound state (fig. 1). This regulatory cy-
cle is primarily controlled by three distinct families of
proteins, guanine exchange factors (GEFs), GTPase-
activating proteins (GAPs), and guanine nucleotide
dissociation inhibitors (GDIs). Upon GTP-loading, a
conformational change takes place that allows Rho
proteins to interact with several downstream effectors
that ultimately process the information and propagate
the signal within the cell (table 1). These effectors are
subclassified as those with no intrinsic or with intrin-
sic enzymatic activity and might be specific to one or
more Rho GTPases2. 
Early studies demonstrated that murine fibroblasts
that overexpressed constitutively active mutant RhoA,
Rac1 or Cdc42 were tumorigenic in syngeneic mice11-13.
Furthermore, Rho-transformed murine fibroblasts
developed distant lung metastasis as determined with
experimental metastasis studies13-16. In addition, besi-
des constituting oncogenes on their own, Rho pro-
RhoC, RhoG, Cdc42, TC10, Rac1, Rac2, Rac3,
Rho6/Rnd1, Rho7/Rnd2, Rho8/Rnd3, RhoE, RhoD,
RhoH and Wrch1-2, 10. These proteins catalyze the hy-
Fig. 1. Rho GTPases regulatory Cycle: GTP loading is ca-
talyzed by Guanine Exchange Factors (GEF).  Once bound
to GTP Rho proteins undergo a complex conformational
change that permits the interaction with downstream ef-
fector proteins. Inactivation occurs through the hydrolysis
of GTP to GDP catalyzed by the synergistic effect of the in-
trinsic Rho GTPase activity with the enhancement of Rho
GAPs (GTPase: Activating Proteins).
Inactive State Active State
GEFs
(Dbl, Ost, Vav)
GDP Rho
GDI
GAPs
(p50RhoGAP,
p190GAP)
GDI
RhoGTP
Conformational
change
Interaction with
Downstream effectors
TABLE 1. Effectors for Rho proteins and their involvement in cell transformation, metastasis and apoptosis
Biological Effects
Effectors RhoGTPases
Proliferation Metastasis Apoptosis 
Rho
ROCK family + + +
PKN family Rac (PRK2) + +
Citron Kinase +
Citron
Rhotekin
Rhophilin
mDia1/2 ?
DAG q Kinase
PLD Rac/Cdc42 + +
PIP5Kinase
Rac/Cdc42
WASP family Cdc42/Rac1 +
IQGAP1/2 Cdc42/Rac1 +
PAK family Cdc42/Rac1 + + +
ACK1/2 Cdc42 + +
POSH +
POR1 Rac
Borg family Cdc42/TC10
MRCKa /b Cdc42
MLK-3 Cdc42/Rac1 + +
MEKK-1/4 Cdc42/Rac1 + +
PI3K Rac/Cdc42(?) + + 
p70S6kinase + ?
p67PHOX +
CIP4 Cdc42 +
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teins are necessary for cell transformation under se-
veral oncogenic stimuli. For instance, Ras and Rho
GTPases-mediated transformation are not separate
events, and the pathways controlled by both families
of proteins form a complex signaling weave resulting
in tumorigenesis17-24. In this sense, inhibition of
RhoA, Rac1 or Cdc42, via ectopic expression of their
dominant negative mutants, in Ras-transformed fi-
broblasts prevents cell proliferation, anchorage-inde-
pendent growth and in vivo tumor formation20-22. The
same holds true for tumors of epithelial nature in
which Ras is the predominant oncogene17. Rho signa-
ling is also necessary for aberrant growth promoted
by several other oncogenic pathways including
EGFR, IGFR, MET, RET and G-protein coupled re-
ceptors24-30. 
Much work has been done in the past decade to elu-
cidate the mechanisms whereby aberrant signaling
downstream of Rho GTPases leads to an efficient tu-
morigenic phenotype. As mentioned above, several
effectors have been cloned and their functions cha-
racterized1-5. With respect to tumorigenesis ROCK,
PAK, and IQGAP are among the best studied, and
their contribution to Rho-mediated cell proliferation
and invasion are fairly well studied (for extensive re-
views on this topic see references 1-2, 6 and 9). In
addition, several works suggest that regulation of
transcription might be a key mechanism for Rho-
promoted oncogenesis. Due to space limitations, in
this review a summary of the incidence and implica-
tion of different Rho family members in human tu-
mors will be made. 
DYSREGULATION OF RHO GTPASES
SIGNALING IN HUMAN TUMORS
One determinant difference between Ras and Rho pro-
teins with respect to human cancers is the lack of do-
minant point mutations that result in constitutive bin-
ding to GTP31-33. However, although no point mu-
tations of Rho GTPases in human tumors have been
found to date, overexpression of either the GTPase it-
self or mutation of some upstream or downstream ele-
ment of Rho signaling has been detected in many hu-
man tumors. Thus, Rho signaling is modified in a large
variety of human tumors as indicated in table 2 and ta-
ble 3. The section below summarizes the incidence of
Rho signaling dysregulation in human tumors with
respect to different stages of tumor development. 
PANCREATIC TUMORS
One of the first evidences of overexpression of a
member of the Rho family of GTPases came with stu-
dies on pancreatic carcinogenesis34. In this study the
expression of RhoA, RhoB and RhoC in 33 cases of
ductal adenocarcinoma of the pancreas was studied
through RT-PCR and protein level. Overexpression of
RhoC, but not RhoA or RhoB, with respect to non-ma-
lignant tissue correlated with tumor grade, with hig-
her expression in metastatic lesions when compared
to primary tumours. In this sense, carcinoma tissue
from lymph node metastases displayed very high le-
vels of RhoC. Finally, RhoC was determined to be a
marker of poor prognosis. As well, it was determined
that overexpression of RhoC is an event independent
of K-ras mutation.
Although overexpression of RhoA was not detected in
any pancreatic tumoral tissue, nevertheless it might
also be involved in pancreatic cancers. Two 3-hy-
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TABLE 3. Dysregulation of dowsntream effectors of Rho
GTPases in different human tumors. PAKs are effectors to
Rac 1 and Cdc42; ACK is a downstream effector to Cdc42;
ROCK ser/thr kinases are effectors to Rho A and Rho C;
IQGAP interact with Rac 1 and Cdc42; WASP and WAVE
proteins are effectors to Cdc 42 and Rac 1 respectively
Type of tumor PAKs ACK1 ROCK IQGAP WASP
Breast + + +
(IBC/no-IBC)
Melanoma + +
Colon + + +
Testicular +
Ovarian +
Pancreas +
Osteosarcoma +
Neuroblastoma WAVE
Prostate +
Liver +
TABLE 2. Dysregulation of Rho GTPases in different human
tumors. (+) indicates overexpression of the indicated
GTPase. Rac 2, Rac 3 indicates overexpression of this
member of the family
Type of tumor RhoC RhoA Rac 1 Cdc42
Breast + + + +
(IBC/no-IBC) Rac3
Melanoma + + +
Colon + + +
Head and + Rac2 +
NeckSCC
Testicular – +
(germiline)
Ovarian +
Pancreas +
Neurobastoma
Osteosarcoma +
Prostate +
Lung + + + +
Liver +
Leukemias +
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droxy 3-methylglutaryl coenzyme A (HMG-CoA) in-
hibitors, fluvastatin and lovastatin inhibit human
pancreatic cancer cell invasion and metastasis35-36.
This family of HMG-CoA inhibitors prevents the synt-
hesis of cholesterol precursors, such as farnesyl py-
rophosphate and geranylgeranyl pyrophosphate, ne-
cessary for proper membrane translocation of Ras
and Rho proteins. Treatment with this family of inhi-
bitors results in an efficient mislocalization of Ras
and Rho proteins and their subsequent inhibition. In
this sense, treatment of pancreatic cancer cell lines
with both drugs results in efficient RhoA mislocaliza-
tion and inhibition, leading to a reduction of the num-
ber of liver metastases produced by these cells when
injected in mice. Furthermore, inhibition of EGF-in-
duced cell invasion of pancreatic cells was achieved
upon fluvastatin and lovastatin treatment, in a RhoA-
dependent manner35.
Although both RhoA and RhoC are involved in pan-
creatic cancers, several issues need to be addresses in
future studies. For instance, no information about the
pathways downstream of RhoC involved in the pro-
gression of pancreatic carcinomas is available. Furt-
hermore whereas RhoC overexpression is indepen-
dent on K-ras status, the same has not been tested
with RhoA. Studies that establish a correlation, if any,
between RhoC overexpression or K-ras mutation with
RhoA activity in pancreatic cancers should provide
useful information as to decide what better antitumo-
ral treatment is to be used. 
BREAST TUMORS
Increased expression of RhoC in other human tumors
has been detected since then. Differential display of
an inflammatory breast cancer (IBC)-derived cell li-
nes with respect to primary cells was carried out and
nine different transcripts were shown to be present in
the tumoral cell lines and absent in the primary cells,
of which one was found to be RhoC37. IBC is the most
aggressive form of breast cancer that is highly infil-
trative and metastatic with poor prognosis for the pa-
tients. Furthermore, this result was confirmed using
in situ hybridization that indicated that approximately
90% of inflammatory breast tumors, and 38% of non-
inflammatory breast tumors, overexpressed RhoC.
The same group then investigated whether overex-
pression of RhoC was a pro-tumorigenic factor in IBC
or a mere consequence of tumor genetic instability.
Overexpression of wild type RhoC in primary human
mammary epithelial cells enables the cells to grow on
anchorage independent conditions38. Furthermore
these cells were highly motile and tumorigenic when
injected in athymic mice mimicking the tumoral phe-
notype of IBC-derived cell lines. It was found that
these cells produce and secrete high levels of proan-
giogenic factors such as vascular endothelial growth
factor (VEGF), basic fibroblast growth factor (bFGF),
interleukin-6 (IL-6), and interleukin-8 (IL-8) when
compared to normal untransformed parental cells39.
Overexpression of RhoA, RhoB and RhoC, but not
Rac1, correlates with tumor grade with high expres-
sion in grade III breast tumors compared to grade I.
Surprisingly, all three RhoA, Rac1 and Cdc42 were
overexpressed in 100% of all tumoral breast tissues
analyzed, and non-detectable in the normal tissue40-41.
This observation suggests that all three GTPases
might be important for breast cancer progression, ho-
wever it should be determined whether inhibition of
each GTPase affects breast tumor growth.
Bouzahzah et al (2001) have recently elegantly
shown that expression of dominant negative RhoA,
Rac1 or Cdc42 in rat mammary adenocarcinoma
cells affects tumor cell growth in vivo and reduce in-
travasation into the peripheral blood, thus inhibiting
the formation of lung metastases42. Other studies ha-
ve indirectly shown an important role of RhoA in
breast carcinogenesis. For instance, treatment of
highly metastatic breast cancer cell-lines with an in-
hibitor of 3-hydroxy 3-methylglutaryl coenzyme A
reductase (HMG CoA reductase), termed cerivasta-
tin, reduces the metastatic potential of these cells43.
As already mentioned, HMG-CoA reductase inhibi-
tors prevent RhoA and Ras membrane localization
and activation. MDA-MB-231 cells treated with ceri-
vastatin have impaired cell proliferation and inva-
sion through matrigel. However, poorly metastatic
breast cancer cells such as MCF-7 are less sensitive
to cerivastatin, suggesting that RhoA might be more
significantly overexpressed in late stages of breast
cancer as with other tumors. The effects elicited by
this inhibitor were determined to be due to RhoA-,
but not Ras-mislocalization from the cell membra-
ne since geranylgeranylation but not farnesylation
counteracted the inhibitory effect of cerivastatin. In-
terestingly, treatment with cerivastatin resulted in
RhoA-dependent inhibition of urokinase and MMP-9
expression further indicating that both these proteins
are downstream targets of Rho involved in Rho-me-
diated tumorigenesis. 
A number of other studies have pointed out a role of
RhoA in human breast tumor progression and metas-
tasis exerted by the CD44 hyaluronan receptor44, 45.
CD44 is expressed in human breast tumors and is a
promoter of both cell growth and metastasis of tumo-
ral cells. RhoA and CD44 directly interact in vivo in
highly metastatic human breast cancer cell-lines re-
sulting in RhoA activation. More importantly, inhibi-
tion of Rho signaling results in the abrogation of the
metastatic phenotype elicited by CD44.
Dysregulation of another member of the Rho family
of GTPases, Rac3, closely related to Rac1 has been de-
tected in breast cancer46. Highly proliferative breast
cancer cells MDA-MB 435, T47D, and MCF-7 but not
Rev Oncol 2003;5(2):70-8 7327
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normal breast cell lines or less proliferative breast
cancer cells, contain constitutive active Rac3 signa-
ling, in a Ras-independent manner. Interestingly, no
dominant activating mutation is detected in Rac3 it-
self, suggesting that a regulatory protein might be im-
paired resulting in high constitutive Rac3 signaling.
As also observed for RhoC, expression of a dominant
negative mutant Rac3 (N17) leads to inhibition of S-
phase entry and cellular proliferation indicating that
Rac3 hyperactivation promotes cell growth. 
The significance of dysregulation of Rho proteins is
human breast cancer is starting to emerge. However,
whilst it is now clear that overexpression of Rho GT-
Pases takes place in different breast cancer derived
cell lines and in tumoral tissues, the underlying me-
chanisms that follow Rho activation that result in the
tumoral phenotype are mostly unknown. Some of
the effectors to Rho GTPases involved in breast can-
cer have been recognized and will be discussed be-
low. The specific pattern of Rho overexpression at dif-
ferent stages of tumor progression need to be further
clarified. Furthermore, it should be determined whet-
her Rho proteins are pivotal towards cell proliferation
or motility and invasiveness. This will indicate whet-
her inhibition of Rho GTPases may be used as an an-
titumoral or antimetastatic strategy. Given the high
incidence of breast cancer among women in develo-
ped countries, both the utilization of Rho as markers
for tumor progression and early detection, and inhibi-
tion of Rho function may provide efficient ways to im-
prove treatment of breast cancer in the future.
MELANOMA
RhoC is also overexpressed in highly metastatic mela-
noma cells as determined through DNA array metho-
dology47. And as for breast cancer, overexpression of
RhoC in these cells leads to a highly invasive phe-
notype, pointing to a general role of RhoC in promo-
ting metastasis in human tumors. In addition to
RhoC, melanoma cells also utilize RhoA and Cdc42
to acquire a metastatic phenotype and to promote cell
proliferation48-50. Overexpression of the Eph receptor
and ephrins in melanomas has been detected, as well
as in other human tumors. Eph receptor signaling in-
duces cytoskeletal changes necessary for the invasive
capacity of melanoma cells in a RhoA-dependent
manner48. RhoA mediates cell rounding and mem-
brane blebbing that take place during detachment
and migration of the cells, thus directly providing the
structural background for proper metastasis. As well,
RhoA directly interacts and is activated by GM3 gan-
glioside, a melanoma-associated antigen50. A second
melanoma cell surface antigen named melanoma
chondroitin sulphate proteoglycan (MCSP) implicated
in melanoma cell growth and invasion signals
through Cdc42 to promote cell-spreading49. Accor-
dingly, constitutively active Cdc42 is found in mela-
noma cells that express MCSP proteoglycan. At last,
fusion of the RhoH gene to BCL6 gene in non-Hodg-
kin’s lymphoma (NHL) has been detected in some ca-
ses of NHL, although its implication in proliferation
has not yet been determined47. 
COLORECTAL TUMORS
It has been proposed that a high proportion of colon
cancers overexpress RhoA40. Furthermore, several as-
pects of colon tumor biology have been related to Rho
GTPases. For instance, proteomic analysis of 15 nor-
mal colon specimens and 13 colonic polyps revealed
that RhoGDI is underexpressed in the polyps compa-
red to the normal colon tissue51. Although, RhoA was
not overexpressed in any polyp analyzed, the low ex-
pression of RhoGDI implies that RhoA activity might
be enhanced in the polyp with respect to the normal
tissue. At last, leptin receptor and leptin-induced mi-
gration of colonic epithelial cancer cells, such as Lo-
Vo, HCT-8/511, and Caco-2, is dependent on RhoA
and Rac1, since introduction of dominant negative
mutants of these completely abolished invasiveness of
the tumoral cells52.
LUNG TUMORS
As with colon cancer, it has been proposed that lung
cancers overexpress RhoA40. Again, little recent data
is available with larger sample numbers or with res-
pect to the correlation between tumor grade and Rho
overexpression. With respect to overexpression, a lar-
ge percentage of over 50 stage I non-small cell lung
carcinomas contained moderate to high overexpres-
sion of Rac1 although with no prognostic informa-
tion. Recently, Varker et al (2003) have further studied
the expression pattern of RhoA small cell lung carci-
noma and non-small cell lung carcinoma. They have
found that expression and activation of RhoA is grea-
ter in SCLC cell lines than in NSCLC cell lines53. As
well, they have observed that inhibition of RhoA in
both SCLC cell lines results in cell-cell compaction,
adhesion and spreading on collagen IV. On the other
hand, inhibition of RhoA in NSCLC cells induces cell
spreading. Interestingly, cell proliferation is reduced
by Rho inactivation in the majority of the NSCLC cell
lines, but not the SCLC cell lines. 
Moreover, other works have already pointed a role of
RhoA in lung carcinogenesis. For instance, both RhoA
and H-Ras repress the expression of nitric oxide synt-
hase-2 (NOS-2) in a lung cancer-derived cell line
A54954. NOS-2 activity is related to reduced prolifera-
tion, thus Rho would presumably eliminate this 
antiproliferative signal in lung carcinogenesis. And
inhibition of RhoA by C3 exoenzyme or through ADP-
ribosylation leads to an increase in cadherin-based
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adhesion and loss of motility of small-cell lung carci-
noma cells54. As for other human cancers, the role of
Rho GTPases in lung cancer appears to be dichoto-
mous promoting cell proliferation and cell motility or
invasion. 
OTHER TUMORS
Other types of human tumors contain alterations in
Rho signaling. This is the case of testicular germ cell
tumors that display high levels of RhoA, but not RhoB
or RhoC55-56. The level of RhoA mRNA is greater in
tissue obtained from the testis tumor than in normal
tissue. Furthermore, mixed tumors with seminoma
and nonseminoma contain higher levels of RhoA than
tumors with only seminoma, indicating that expres-
sion of RhoA correlates with tumor stage and aggres-
siveness.
Rho GTPases are dysregulated or overexpressed in a
number of other human tumors. For instance, migra-
tion and in vivo invasiveness of human hepatocellu-
lar carcinoma cell lines is dependent on RhoA, since
inhibition of RhoA signaling leads to a significant 
reduction of intrahepatic metastasis produced by he-
patocellular carcinoma cell lines injected in nude mi-
ce57-58. As well, RhoA, Rac2 and Cdc42 are overex-
pressed in human head and neck squamous cell
carcinomas59. At last, both mRNA and proteins levels
of RhoA are elevated in pelvic/ureteric cancer with
an increase in lymph node metastasis and with poor
prognosis60. 
RHO GTPASES REGULATORS IN HUMAN
CANCERS
Aberrant expression of upstream activators of Rho
GTPases has been detected in several human tumors.
In this sense, it has been proposed that increased
RhoA activity might occur as a consequence of the
overexpression of a RhoGEF termed GEF720 in neu-
roblastomas61. Another example for the dysregulation
of a RhoGEF in human cancers has been found in re-
nal carcinomas. Although Tiam-1 expression correla-
tes inversely with renal tumoral invasion, an effect
predicted for Tiam-1 in invasiveness of epithelial
cells, mutations in Tiam-1 have been found in renal
carcinomas that result in a constitutively active pro-
tein that leads to sustained Rac1 activation62-63. Re-
cently, Malliri et al (2002) have generated mice that
lack Tiam1 that will enable to study the specific role
of Tiam1 signaling in different tumor models. For ins-
tance, in a model of skin carcinogenesis it was found
that Tiam1 is necessary for tumor initiation and pro-
motion, but opposes tumor progression in a Ras-de-
pendent manner64. These results are quite interesting
since they indicate that the role of Tiam1 in tumorige-
nesis is tumor specific. 
Other Rho GEFs are implicated in human cancers.
For instance, fusion of a RhoGEF to MLL, termed
LARG, and mutation of leukemia-associated RhoGEF
have been found in acute myeloid leukemias (AML)
and leukemias, respectively65-66. LARG has been later
shown to activate RhoA in vivo suggesting a role of
LARG/RhoA in progression of leukemia67. In addi-
tion, loss of RhoGDI expression in advanced metasta-
tic bladder cancers compared to less aggressive tu-
mors has been detected, suggesting that RhoA might
play an important role in the metastatic cascade of
bladder carcinoma68.
GENETIC ALTERATION IN RHO GTPASES
Although no point mutations in any member of the
Rho family GTPases have been found in any human
tumor, two independent works have described the ex-
pression of Rac1 splice variants in breast and colon
cancers69-70. In breast carcinomas a Rac1 isoform,
termed Rac1b, with an insertion of 19 codons next to
switch II was detected. This mutation promotes fast
cycling of both GTP-binding and hydrolysis leading to
an overall increase in Rac1 signaling. Furthermore,
Rac1b is significantly highly expressed in breast can-
cer tissues compared to normal breast tissue with
high expression in ductal carcinoma-in situ, primary
breast cancer and lymph node metastases69. With res-
pect to colon cancer, high expression of a Rac1 va-
riant, also termed Rac1b, with a similar insertion of
19 amino acids adjacent to the switch II was detected
in colorectal cancers with respect to normal non-tu-
moral tissue70. Expression of Rac1b splice variant
was also mostly expressed in skin and epithelial tis-
sues from the intestinal tract, but the expression level
was enhanced in the tumoral tissue. The recent clo-
ning and characterization of the structure of the Rac1
gene, with the identification of its promoter region
will provide useful to understand the differential ex-
pression of Rac1 between tumoral and normal tissue
as well as providing clues as to how Rac1 splice va-
riants arise71. 
CONCLUDING REMARKS
The specific role of Rho GTPase signaling in all the
different human cancers described above is starting to
be understood. The information obtained on Rho sig-
naling pathways and effects through conventional and
new biochemical techniques with established cell li-
nes may provide essential to delineate the elements of
these pathways in each of the tumors described above.
The precise role of Rho in every different tumor will
need to be determined in order to better predict the tu-
mor progression and to better treat a specific tumor. 
One important issue to study with concern to Rho ex-
pression in different human tumors is the cause and
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nature of such expression. So far no activating muta-
tions have been found within the coding sequence of
Rho proteins in human tumors. In addition, although
no changes in the levels of Rho GTPases mRNA levels
have been detected in colon and breast tumor compa-
red to normal tissue, this is not the case for testicular
germ tumors where an increase in Rho mRNA level is
observed. Therefore, to date it seems that Rho overex-
pression in human tumors is not a genetic event, but
it rather depends on other genetic instabilities or tu-
mor environment. The characterization of these ele-
ments that govern Rho dysregulation will provide
useful information to better understand the role of
Rho in different stages of tumor. As well, it will set the
ground for a better target-based anticancer treatment.
Many works are already available that have dissected
some of these pathways downstream of Rho GTPases
that contribute to the proliferative and the metastatic
signals. As well, recent findings in Rho-mediated
transcriptional regulation with respect to tumorigene-
sis have been made that further strengthen the idea
that many signal transduction pathways are regulated
by Rho GTPases that contribute to the overall biologic
outcome. 
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